Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial”

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference”